Modeling the Influence of Cyclodextrins on Oral Absorption of Low-Solubility Drugs: I. Model Development

被引:24
作者
Gamsiz, Ece Dilber [1 ]
Miller, Lee [2 ]
Thombre, Avinash G.
Ahmed, Imran [2 ]
Carrier, Rebecca Lyn [1 ]
机构
[1] Northeastern Univ, Snell Engn Ctr 342, Boston, MA 02115 USA
[2] Pfizer Inc, Groton, CT 06340 USA
关键词
cyclodextrins; poorly-soluble drugs; bioavailability; modeling; BETA-CYCLODEXTRIN; INTESTINAL-ABSORPTION; PHARMACEUTICAL APPLICATIONS; DISSOLUTION RATE; DOSAGE FORMS; BIOAVAILABILITY; DELIVERY; COMPLEXATION; IMPROVEMENT; FUTURE;
D O I
10.1002/bit.22523
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The ability to quantitatively predict the influence of a solubilization technology on oral absorption would be highly beneficial in rational selection of drug delivery technology and formulation design. Cyclodextrins (CDs) are cyclic oligosaccharides which form inclusion complexes with a large variety of compounds including drugs. There are many studies in the literature showing that complexation between CD and drug enhances oral bioavailability and some demonstrating failure of CD in bioavailability enhancement, but relatively little guidance regarding when CD can be used to enhance bioavailability. A model was developed based upon mass transport expressions for drug dissolution and absorption and a pseudo-equilibrium assumption for the complexation reaction with CD. The model considers neutral Compound delivered as a physical mixture with CD in both immediate release (IR) and controlled release (CR) formulations. Simulation results demonstrated that cyclodextrins can enhance, have no effect, or hurt drug absorption when delivered is a physical mixture with drug. The predicted influence depends on interacting parameter values, including solubility, drug absorption constant, binding constant, CD:drug molar ratio, dose, and assumed volume of the intestinal lumen. In general, the predicted Positive influence of dosing as a physical mixture with CD was minimal, alluding to the significance of dosing as a preformed complex. The model developed enabled examination of which physical and chemical properties result in oral absorption enhancement for neutral drug administered as a physical mixture with CD, demonstrating the utility of modeling the influence of a drug delivery agent (e.g., CID) on absorption for rational dosage form design, Biotechnol. Bioeng. 2010;105: 409-420. (C) 2009 Wiley Periodicals, Inc.
引用
收藏
页码:409 / 420
页数:12
相关论文
共 47 条
[1]   Predicting the impact of physiological and biochemical processes on oral drug bioavailability [J].
Agoram, B ;
Woltosz, WS ;
Bolger, MB .
ADVANCED DRUG DELIVERY REVIEWS, 2001, 50 :S41-S67
[2]  
Arima H, 2002, RRD CHE PHA, V2, P155
[3]   NMR diffusion coefficient study of steroid-cyclodextrin inclusion complexes [J].
Cameron, KS ;
Fielding, L .
MAGNETIC RESONANCE IN CHEMISTRY, 2002, 40 :S106-S109
[4]   The utility of cyclodextrins for enhancing oral bioavailability [J].
Carrier, Rebecca L. ;
Miller, Lee A. ;
Ahmed, Mran .
JOURNAL OF CONTROLLED RELEASE, 2007, 123 (02) :78-99
[5]   Cyclodextrins in drug delivery: An updated review [J].
Challa, R ;
Ahuja, A ;
Ali, J ;
Khar, RK .
AAPS PHARMSCITECH, 2005, 6 (02)
[6]   Cyclodextrin-based pharmaceutics: Past, present and future [J].
Davis, ME ;
Brewster, ME .
NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (12) :1023-1035
[7]   MIXING-TANK MODEL FOR PREDICTING DISSOLUTION RATE CONTROL OF ORAL ABSORPTION [J].
DRESSMAN, JB ;
FLEISHER, D .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1986, 75 (02) :109-116
[8]   ABSORPTION POTENTIAL - ESTIMATING THE FRACTION ABSORBED FOR ORALLY-ADMINISTERED COMPOUNDS [J].
DRESSMAN, JB ;
AMIDON, GL ;
FLEISHER, D .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1985, 74 (05) :588-589
[9]   PHYSICOCHEMICAL MODEL FOR DOSE-DEPENDENT DRUG ABSORPTION [J].
DRESSMAN, JB ;
FLEISHER, D ;
AMIDON, GL .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1984, 73 (09) :1274-1279
[10]   Improving the dissolution and bioavailability of nifedipine using solid dispersions and solubilizers [J].
Emara, LH ;
Badr, RM ;
Abd Elbary, A .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2002, 28 (07) :795-807